Latest Breaking News On - Mark frattini - Page 1 : comparemela.com

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaNew yorkFrance generalAshleyr robinsonArthur strilMark frattiniPascalyne wilsonPatricia sosa navarroAmerican society of hematologyCellectis the company euronext growthEuropean medicines agencyEuropean unionSecurities exchange commissionCommittee for orphan medicinal productsEuropean commission

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell

United statesNorth carolinaFrance generalNew yorkPatricia sosa navarroPascalyne wilsonMark frattiniAshleyr robinsonArthur strilEuropean medicines agencyCellectis the company euronext growthAmerican society of hematologyEuropean commissionSecurities exchange commissionEuropean unionCommittee for orphan medicinal products

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

NEW YORK, May 17, 2023 Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data. | May 17, 2023

North carolinaUnited statesFrance generalNew yorkBeatriz aranda orgillesMark frattiniDaniel leeArthur strilPascalyne wilsonAshleyr robinsonAmerican society of hematologyCellectis the company euronext growthSecurities exchange commissionClinical sciences at cellectisTeam leader at cellectisAmerican society of gene

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

NEW YORK, May 17, 2023 Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data. | June 12, 2023

New yorkUnited statesNorth carolinaFrance generalDaniel leeBeatriz aranda orgillesAshleyr robinsonMark frattiniArthur strilPascalyne wilsonTeam leaderEu pressAmerican society of hematologySecurities exchange commissionAmerican society of geneCellectis the company euronext growth

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesNorth carolinaFrance generalMark frattiniDaniel leeBeatriz aranda orgillesAshleyr robinsonArthur strilPascalyne wilsonAmerican society of hematologyClinical sciences at cellectisAmerican society of geneCellectis the company euronext growthTeam leader at cellectisSecurities exchange commission